In the past week, QURE stock has gone down by -9.49%, with a monthly gain of 7.96% and a quarterly surge of 11.12%. The volatility ratio for the week is 1.27%, and the volatility levels for the last 30 days are 3.51% for uniQure N.V The simple moving average for the last 20 days is -4.67% for QURE stock, with a simple moving average of 32.46% for the last 200 days.
Is It Worth Investing in uniQure N.V (NASDAQ: QURE) Right Now?
QURE has 36-month beta value of 0.09. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for QURE is 49.67M, and currently, short sellers hold a 15.01% ratio of that float. The average trading volume of QURE on June 18, 2025 was 1.79M shares.
QURE) stock’s latest price update
The stock of uniQure N.V (NASDAQ: QURE) has decreased by -2.12 when compared to last closing price of 15.11. Despite this, the company has experienced a -9.49% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-11 that ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) — uniQure N.V.
Analysts’ Opinion of QURE
Many brokerage firms have already submitted their reports for QURE stocks, with Chardan Capital Markets repeating the rating for QURE by listing it as a “Buy.” The predicted price for QURE in the upcoming period, according to Chardan Capital Markets is $38 based on the research report published on April 01, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to QURE, setting the target price at $20 in the report published on October 10th of the previous year.
QURE Trading at 8.61% from the 50-Day Moving Average
After a stumble in the market that brought QURE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QURE starting from Kapusta Matthew C, who sale 28,341 shares at the price of $10.29 back on Mar 04 ’25. After this action, Kapusta Matthew C now owns 651,454 shares of uniQure N.V, valued at $291,629 using the latest closing price.
Abi-Saab Walid, the Chief Medical Officer of uniQure N.V, sale 1,350 shares at $10.29 during a trade that took place back on Mar 04 ’25, which means that Abi-Saab Walid is holding 151,903 shares at $13,891 based on the most recent closing price.
Stock Fundamentals for QURE
Current profitability levels for the company are sitting at:
- -8.55 for the present operating margin
- 0.41 for the gross margin
The net margin for uniQure N.V stands at -10.77. The total capital return value is set at -0.3. Equity return is now at value -241.16, with -31.64 for asset returns.
Based on uniQure N.V (QURE), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -2.51. The debt to equity ratio resting at 1.97. The interest coverage ratio of the stock is -5.31.
Currently, EBITDA for the company is -160.75 million with net debt to EBITDA at 0.98. When we switch over and look at the enterprise to sales, we see a ratio of 32.61. The receivables turnover for the company is 1.56for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.99.
Conclusion
To put it simply, uniQure N.V (QURE) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
